LuminUltra to Develop Menu of Portable PCR Products on the CubeX Platform

OTTAWA, CANADA, September 9, 2024 – Genomadix (genomadix.com), the global leader in point of care precision medicine molecular diagnostics, today announced that it has licensed its CubeX Open Platform technology to LuminUltra, a global leader in applied molecular diagnostics for the water, energy and food & beverage markets, to enable the company to develop a menu of PCR products for applied markets based on the CubeX platform and consumables. As part of the deal, Genomadix has also divested its Legionella business to LuminUltra.
The Genomadix CubeX Open Platform, launched in the summer of 2024, is a highly portable real-time PCR platform available to industry partners to develop  products for applications in diverse markets where PCR-grade accuracy, speed, portability, simplicity, and low cost are attractive features.
In addition to the CubeX license, LuminUltra will take over the manufacturing, global sales and marketing of the industry-leading Genomadix legionella on-site quantitative PCR test. LuminUltra will also invest in the development of next-generation legionella products based on the CubeX platform.

CubeX Open Platform is available for strategic partnerships
Steve Edgett, CEO of Genomadix, stated “Genomadix is focused on the development and commercialization of precision medicine tests on the Cube and licensing our CubeX Open Platform to strategic partners. LuminUltra was the perfect home for the legionella business that we had nurtured under the Spartan Bioscience brand. We intend to support a seamless transition with our customers and are thrilled that LuminUltra will bring scale, expertise, and focus to the Legionella business. This agreement is our first CubeX Open Platform strategic partnership. We look forward to more partnerships in other markets in the future.”
Pat Whalen, LuminUltra CEO, added “With this latest addition to our portfolio, we can now help even more customers around the world to rapidly and accurately monitor and manage against the proliferation of harmful Legionella bacteria. This rapid, point of use solution complements our existing testing offerings by providing a best-in-class solution for those time sensitive, ‘in-field’ use cases that demand near-real-time and accurate results to confidently inform critical operational decisions and actions. Access to the Genomadix CubeX Platform will enable us to offer additional innovative on-site, rapid PCR products in the future.” The transaction was completed on July 31, 2024. Terms were not disclosed.

About Genomadix
Based in Ottawa, Canada, Genomadix Inc. is a pioneer in real-time qPCR point of need technology. The Genomadix Cube is a molecular diagnostic instrument capable of performing tests for precision medicine genotyping on a sample-to-result platform. The portable size, ease of use, and on-demand processing capability enables users to generate time-critical results in approximately one hour. The Cube platform is also available as an open platform called CubeX that can be used to design, develop and run any qPCR test for research and product development purpose. Applications of the Genomadix Cube technology include but are not limited to precision medicine, clinical diagnostics and environmental testing. For more information, visit www.genomadix.com.

Media contact: Tara Linseman, Sr. Manager of Product Management
[email protected] +1-613-228-7756

About LuminUltra
Founded in 1995, LuminUltra is a biological diagnostic testing company headquartered in Canada with operations in six countries. Widely recognized as the global leader in applied molecular diagnostics for the water, energy and food & beverage markets, it was also a key supplier of COVID-19 clinical testing reagents to the Government of Canada. Customers in over 80 countries trust LuminUltra’s technology, production reliability and history of customer service excellence to deliver their essential services in a safe-state. At the same time, LuminUltra fosters a culture of innovation and agility and is on an accelerated growth path, acquiring multiple companies in recent years and forming a partnership with the specialized private equity firm XPV Water Partners.

Media contact: Gene Schilling, Director of Marketing
[email protected] +1-519-990-0084